Additional_JJ Information_NN 159_CD ADDITIONAL_NNP INFORMATION_NNP HISTORY_NNP AND_CC DEVELOPMENT_NNP OF_IN THE_DT COMPANY_NNP Directors_NNS are_VBP not_RB required_VBN to_TO retire_VB at_IN For_IN all_DT general_JJ meetings_NNS ,_, a_DT quorum_NN of_IN two_CD AstraZeneca_NNP PLC_NNP was_VBD incorporated_VBN in_IN England_NNP a_DT particular_JJ age_NN ._.
shareholders_NNS present_VBP in_IN person_NN or_CC by_IN proxy_NN and_CC Wales_NNP on_IN 17_CD June_NNP 1992_CD under_IN the_DT is_VBZ required_VBN ._.
It_PRP is_VBZ a_DT public_JJ limited_JJ Directors_NNS are_VBP required_VBN to_TO beneficially_RB own_JJ company_NN domiciled_VBD in_IN the_DT UK_NNP ._.
The_DT Companys_NNP Ordinary_NNP Shares_NNP in_IN the_DT Company_NN of_IN an_DT aggregate_JJ Shareholders_NNS and_CC their_PRP$ duly_RB appointed_VBN proxies_NNS registered_VBD number_NN is_VBZ 2723534_CD and_CC its_PRP$ registered_VBN nominal_JJ amount_NN of_IN $_$ 125_CD ._.
At_IN present_JJ ,_, this_DT and_CC corporate_JJ representatives_NNS are_VBP entitled_VBN to_TO office_NN is_VBZ at_IN 15_CD Stanhope_NNP Gate_NNP ,_, London_NNP W1K_NNP means_VBZ they_PRP must_MD own_VB at_IN least_JJS 500_CD shares_NNS ._.
be_VB admitted_VBN to_TO general_JJ meetings_NNS ._.
From_IN February_NNP 1993_CD until_IN April_NNP 1999_CD ,_, the_DT Company_NNP Rights_NNP ,_, preferences_NNS and_CC restrictions_NNS Limitations_NNPS on_IN the_DT rights_NNS to_TO own_VB shares_NNS was_VBD called_VBN Zeneca_NNP Group_NNP PLC._NNP ._.
On_IN 6_CD April_NNP attaching_VBG to_TO shares_NNS There_EX are_VBP no_DT limitations_NNS on_IN the_DT rights_NNS to_TO 1999_CD ,_, the_DT Company_NN changed_VBD its_PRP$ name_NN to_TO The_DT share_NN capital_NN of_IN the_DT Company_NN is_VBZ divided_VBN own_JJ shares_NNS ._.
into_IN 2,400,000,000_CD Ordinary_NNP Shares_NNP with_IN a_DT nominal_JJ value_NN of_IN $_$ 0.25_CD each_DT and_CC 50,000_CD The_DT Company_NN was_VBD formed_VBN when_WRB the_DT Redeemable_JJ Preference_NN Shares_NNS with_IN a_DT nominal_JJ pharmaceutical_JJ ,_, agrochemical_NN and_CC specialty_NN value_NN of_IN 1.00_CD each_DT ._.
The_DT rights_NNS and_CC restrictions_NNS chemical_NN businesses_NNS of_IN Imperial_NNP Chemical_NNP attaching_VBG to_TO the_DT Redeemable_JJ Preference_NNP Industries_NNPS PLC_NNP were_VBD demerged_VBN in_IN 1993_CD ._.
Shares_NNP differ_VBP from_IN those_DT attaching_VBG to_TO Ordinary_NNP In_IN 1999_CD ,_, the_DT Company_NN sold_VBD the_DT specialty_NN Shares_NNS as_IN follows_VBZ :_: chemical_NN business_NN ._.
Also_RB in_IN 1999_CD ,_, the_DT Company_NN merged_VBD with_IN Astra_NNP AB_NNP of_IN Sweden_NNP ._.
In_IN 2000_CD ,_, The_DT Redeemable_JJ Preference_NN Shares_NNS carry_VBP it_PRP demerged_VBD the_DT agrochemical_NN business_NN and_CC no_DT rights_NNS to_TO receive_VB dividends_NNS ._.
merged_VBD it_PRP with_IN the_DT similar_JJ agribusiness_NN of_IN Novartis_NNP AG_NNP to_TO form_VB a_DT new_JJ company_NN called_VBD The_DT holders_NNS of_IN Redeemable_JJ Preference_NN Syngenta_NNP AG_NNP ._.
Shares_NNS have_VBP no_DT rights_NNS to_TO receive_VB notices_NNS of_IN ,_, attend_VB or_CC vote_VB at_IN general_JJ meetings_NNS except_IN The_DT Company_NN owns_VBZ and_CC operates_VBZ numerous_JJ in_IN certain_JJ limited_JJ circumstances_NNS ._.
They_PRP have_VBP R&D_VBN ,_, production_NN and_CC marketing_NN facilities_NNS one_CD vote_NN for_IN every_DT 50,000_CD Redeemable_JJ worldwide_NN ._.
Its_PRP$ corporate_JJ headquarters_NNS are_VBP Preference_NNP Shares_NNP held_VBD ._.
at_IN 15_CD Stanhope_NNP Gate_NNP ,_, London_NNP W1K_NNP 1LN_NNP and_CC its_PRP$ R&D_NNP headquarters_NN are_VBP at_IN SE-151_CD 85_CD On_IN a_DT distribution_NN of_IN assets_NNS of_IN the_DT Company_NN ,_, Sdertlje_NNP ,_, Sweden_NNP ._.
on_IN a_DT winding-up_NN or_CC other_JJ return_NN of_IN capital_NN subject_NN to_TO certain_JJ exceptions_NNS ,_, the_DT holders_NNS MEMORANDUM_NNP AND_CC ARTICLES_NNPS OF_IN ASSOCIATION_NNP of_IN Redeemable_NNP Preference_NNP Shares_NNP have_VBP Objects_NNS priority_NN over_IN the_DT holders_NNS of_IN Ordinary_NNP Shares_NNP As_IN is_VBZ typical_JJ of_IN companies_NNS registered_VBN in_IN to_TO receive_VB the_DT capital_NN paid_VBN up_RP on_IN those_DT England_NNP and_CC Wales_NNP ,_, the_DT Companys_NNP objects_NNS ,_, shares_NNS ._.
which_WDT are_VBP detailed_VBN in_IN the_DT Memorandum_NNP of_IN Association_NNP ,_, are_VBP broad_JJ and_CC wide-ranging_JJ and_CC Subject_JJ to_TO the_DT provisions_NNS of_IN the_DT Companies_NNS include_VBP manufacturing_NN ,_, distributing_VBG and_CC trading_VBG Act_NNP 1985_CD ,_, the_DT Company_NN has_VBZ the_DT right_NN to_TO pharmaceutical_JJ products_NNS ._.
redeem_VB the_DT Redeemable_JJ Preference_NN Shares_NNS at_IN any_DT time_NN on_IN giving_VBG not_RB less_JJR than_IN Directors_NNS seven_CD days_NNS written_VBN notice_NN ._.
Subject_JJ to_TO certain_JJ exceptions_NNS ,_, Directors_NNS do_VBP not_RB have_VB power_NN to_TO vote_VB at_IN Board_NNP meetings_NNS on_IN Action_NNP necessary_JJ to_TO change_VB the_DT rights_NNS matters_NNS in_IN which_WDT they_PRP have_VBP a_DT material_NN interest_NN ._.
of_IN shareholders_NNS In_IN order_NN to_TO vary_VB the_DT rights_NNS attached_VBN to_TO any_DT class_NN The_DT quorum_NN for_IN meetings_NNS of_IN the_DT Board_NNP of_IN of_IN shares_NNS ,_, the_DT consent_NN in_IN writing_NN of_IN the_DT holders_NNS Directors_NNS is_VBZ a_DT majority_NN of_IN the_DT full_JJ Board_NNP ,_, of_IN of_IN three_CD quarters_NNS in_IN nominal_JJ value_NN of_IN the_DT issued_VBN whom_WP at_IN least_JJS four_CD must_MD be_VB Non-Executive_JJ shares_NNS of_IN that_DT class_NN or_CC the_DT sanction_NN of_IN an_DT Directors_NNS ._.
In_IN the_DT absence_NN of_IN a_DT quorum_NN ,_, the_DT extraordinary_JJ resolution_NN passed_VBN at_IN a_DT general_JJ Directors_NNS do_VBP not_RB have_VB power_NN to_TO determine_VB meeting_NN of_IN such_JJ holders_NNS is_VBZ required_VBN ._.
compensation_NN arrangements_NNS for_IN themselves_PRP or_CC any_DT member_NN of_IN the_DT Board_NNP ._.
Annual_JJ general_JJ meetings_NNS and_CC extraordinary_JJ general_JJ meetings_NNS The_DT Board_NNP of_IN Directors_NNS may_MD exercise_VB all_PDT the_DT Annual_JJ general_JJ meetings_NNS and_CC extraordinary_JJ powers_NNS of_IN the_DT Company_NN to_TO borrow_VB money_NN ._.
general_JJ meetings_NNS where_WRB a_DT special_JJ resolution_NN Variation_NN of_IN these_DT borrowing_VBG powers_NNS would_MD is_VBZ to_TO be_VB passed_VBN or_CC a_DT Director_NNP is_VBZ to_TO be_VB appointed_VBN require_VBP the_DT passing_NN of_IN a_DT special_JJ resolution_NN require_VBP 21_CD clear_JJ days_NNS notice_VBP to_TO shareholders_NNS ._.
All_DT other_JJ extraordinary_JJ general_JJ meetings_NNS require_VBP 14_CD clear_JJ days_NNS notice_NN ._.
